Forecasted Opportunity
Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
<p>The National Institute on Drug Abuse (NIDA) intends to publish a Notice of Funding Opportunity (NOFO) to support research on the discovery and development of interventions to prevent and treat substance use disorders (SUDs) and overdose. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the UG3/UH3 activity code. Investigators with expertise and insights in the areas of SUD therapeutics discovery and development are encouraged to begin to consider applying for this new NOFO. Collaborative investigations combining expertise in pharmacology, toxicology, medicinal chemistry, neuromodulation, digital interventions, clinical trials, regulatory science, among others, will be encouraged, and these investigators should also begin considering applying for this application.</p>
Post Date:May 13, 2025
Last Updated Date:May 13, 2025
Opportunity ID: 358937
Opportunity Number: FOR-DA-26-004
Agency Name: National Institutes of Health
Eligible Applicants:
0 - State governments1 - County governments
5 - Independent school districts
6 - Public and State controlled institutions of higher education
7 - Native American tribal governments (Federally recognized)
8 - Public housing authorities/Indian housing authorities
11 - Native American tribal organizations (other than Federally recognized tribal governments)
12 - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
20 - Private institutions of higher education
22 - For-profit organizations other than small businesses
23 - Small businesses





